OMCL - Earnings call transcript Q3 2017

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. My name is Erica and I’ll be your conference operator today. At this time, I would like to welcome everyone to the Omnicell Third Quarter Earnings Announcement. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks there will be a question-and-answer session. Mr. you, Thank Instructions] [Operator Peter Kuipers.

may conference. your You begin

Peter Kuipers

we Thank third At quarter afternoon will and follow only-mode. this and time. Q&A the Omnicell welcome to Later listen XXXX a all at are you. conduct instructions participants a session Good time in will results that conference call.

results include from Lipps, factors to subject risks, expressed and other Joining Randall Chairman, and statements Omnicell me today materially CEO. forward-looking President could to cause or implied. actual that Founder, those is This differ call will uncertainties

undue a these the in more with filed release report to more other not call Future of Please of in detailed is that of For annual SEC. only. conference description events of call reliance filed forward-looking may aware that The and be XX-K statements this of cause the change. Omnicell press forward-looking today. or the the recent on time any XXXX forward-looking risks date reports the you SEC beliefs place the our these passage today, statements date beliefs impact Omnicell this made all Form should refer in on the on to made statements, XX, February on with October as please made on XXXX information simply and are this XX,

for will the is guidance and Randall or our results auto Finally, cover the this prohibited. of conference business third the call provide expressed Omnicell, year. is then quarter XXXX Omnicell, on Inc. rebroadcast our without duplication Inc. will consent the any taping, an property for our and I of written update of first

we will Following our remarks, your take questions. prepared

omnicell.com. earlier the usual, are, results included our was announcement our website section of posted Investor in financial at is which and in quarter third today earnings Relations as Our released

will be prepared same Our section. the posted in also remarks

now me turn the Randall. to over Let call

Randall Lipps

everyone. afternoon Good

is gaining third progress the Series momentum continued that discuss and quarter well every as to XT excited market scaling of our day. introduction We’re results as our

of pleased expand our automation. pharmacy innovation and build leading progress with are continuous to and We platform the industry

year, this and XT far experience both January, and new so have responses for continued great existing which momentum we new our we launched customers. in Specifically Series received

to Secondly April Dispensing of XT which software quarter, XT system management substance new flexibility Aesynt we Series. substances. customers hardware full our allows controlled of launch providing controlled of take on the AcuDose module to efficient and more we workflow dispensing Series rate the in of XT We dispenser launch announced secure in Supply for mobile into the Automated announced through innovative, and advantage pharmacy naturally Last the inventory administration integrate provided automated Pharmacy Manager workflows. capabilities and Central of the

We and facets Pharmacists of Society solutions. and as through we which the and time, ASHP investors in of Day on of interference management. partner capabilities proprietary which showcase platform across that leading and the the synchronization the addition held the improvement performance drive and ecosystem medication this be will cards. also analysts, improvements Earlier acquisition SureMed health development the at to advanced American compliance expanded we to regulatory software internal the blister to for cloud-based automated will Health-System industry medication XXXF Orlando, core X, centers At of we of Innovation adds outcomes multimed and And clinical for our all innovation of Omnicell choice Annual Florida. InPharmics mid-year announced December expanded lastly, positioning operational looking with systems week differentiated meeting medication Omnicell’s the VBM timeline Omnicell new packaging of on solution, leading market the platform

lines and refresh announcements innovation with have frequency. leader, regularly and a we we an annual to broaden technology our As product expect

indicator, bookings announcements ups the marketplace and and this From in that that of within winning XXXX given expect a are This we the of competitive had great quarter business during simultaneous a bookings. around strength of were product third clear never business. it the product annual remainders revenue automated who a we strong perspective will ramp And were two-thirds new Greenfield competitive the is of multiple those the XX% conversion We a had customers cadence conversions. rate of launches is And from before. of year. drive

September sales and product was months conversion that XX%. as the driven new ending For XXXX growth competitive strength base rate opportunities portfolio. the us for cross-selling as new future a gives well by We our across replacement and robust installed our XX upgrade believe and customer XX, platform account expansion,

XT very the by Series customers. is accepted Second, well and received

of week of at sites XXX which XXX at sites, is The delivered April. XXX is which up now to XT had the from end April is we live last over from Series As the day. approximately sites of growing sites, numbers XT every up at are end XXX both

quarter revenue third XX%. of revenue XX% was progressing fourth the quarter. XX% that the above specifically about Series earlier about our Series is in Third, of the scaling expectation now in percentage expect the this from to the well increase XT frame came XT versus We that of percentage to

This assembly We allow consolidate one. of of three and number have lines the the also frame shipment from end ADC to announced this customers GX us and to by year. reduce AcuDose will December of to

last quarter some hurricanes, Irma annual our timing revenue was and in came guidance revenue non-cancelable There service our the third a or are completed is one our below minor as Harvey which slightly in as million, and result drivers also small these timing implementations implementations non-GAAP quarter. grown quarter number call. Despite $XXX quarter slightly This fourth delay successfully And for the timing we the headwind very this there the differentiated the growth guidance through which being implementing the timing Florida. fourth gross third-party of installed hospital And up and agreements contract non-GAAP in quarter which platforms, In in specific rating second Texas and are for in years. is the Non-GAAP was in which because of as impact delays resulted is renewals, third is account. in of provided below Now was of consecutive range earnings to XX have service of guidance revenue large in from consecutive three margin strategies, the in we for growth we for of received growth the in the cost $X.XX, by controls that strong new operating and business Omnicell years organization, catch good acquisitions. the KLAS, growth range expect our XX our scalable EPS have revenue from number improvements consensus. revenue and via prestigious the years, top quarter. middle for honors resulted markets

implementing continuation we for Increasingly, automation to becoming growing of We partner a management customers, to operations the for state-of-the-art we gain In of top the and national developed the of Meridian workflow specifically with the technology large differentiated health to Medical added system momentum system experienced Kimmel clinical in share state-of-the-art United unique scheduled increased Riverside pavilion numerous facilities. network share XXXX, medical nation platforms. Center. in and chain roll the States the in gain Hackensack business five have Omnicell��s honor Automated the and on under and the for as and developing we the hospital leader Management outcomes across for Martin XXXX. share and centers best the existing supply will Center, is a many be market integrated had recently and across believe XT plans that order third in including XXXX-XXXX to Helen years. by the open multiyear specifically strategic Omnicell’s patients. market customers, Hackensack promoting Omnicell have Dispensing technology further to magnet Meridian further Omnicell Medical for hospital and XXX competitive medication it’s our has gained and chosen a our chosen customers standardizing top customer a every new chain our nursing premier to Solutions we within in safety platform With accreditation services Health, thought as and Omnicell great solutions has Meridian we to-date, Health, in to enterprise nation implement medication X% Medication some wins main it’s with Health, consistently implement to efficiency one trend hospital. customers number first quarter, significant conversions, it’s management recognition market the on Omnicell new efficiencies. performing prominent caregivers with and well Automated Health are patient of NYU academic receive solution Medication Riverside wins XT including acquired customer Current quarter. deliver Hackensack Health hospital supply hospitals great healthcare NYU first notable named Dispensing Automated healthcare nationwide and its XXXX In and strategic continued we of family, Omnicell’s customers the XX currently better experience have improve pillar deals facilities and solutions

solutions Additionally Riverside enhanced safety, with newly will workflow. constructed software pharmacy be that improved will central tracking and outfitting automation provide pharmacy security, its’ and

portfolio Houston process strength Consistently month, Omnicell’s Texas in health this wins located dispensing of Center marketplace with are Children’s strategic nation its technology hospitals implementing in in in their the the also Additionally across differentiated systems. Hospital solution to the Omnicell These on a Texas for chosen our Children’s platform. has optimization automated ranked is the the based system. the medication among of improve children’s top Omnicell’s Performance

IV proud We in driven Innovative improvement Dispensing award health systems XT received Series a largest from our were Omnicell of the compounding member industry awarded Vizient recent the XXXX Automated and the Technology country. designated are also solution performance company

as and especially value result feedback who the the designation the brings from with the direct excited interacted to to technology the industry. experts healthcare are products receive is We this of understand it

our competitive Frost of Year. We in innovation Automation superior and named will Global & Pharmacy Omnicell recently leadership performance Vendor as Hospitals’ XXXX are generation, analyst recognized Company and excited growth, Smart The also that the and brand demand excellence positioning. for Omnicell development Sullivan the

expanding believe markets years the we’re coming the last growth for pillar several years. sets up us we also new fueled into well in strategic second Our and

more the pleased customer IV China. verifies and IV based feedback has Omnicell receive to close-door SureMed The of It chosen Tampa support Hospital serving pharmacies, blister Recognizing from chain sterile compounding specialty safer, experiencing that fills globally service Omnicell and effective adopted the pharmacies accurate and and of will independent momentum General automation Germany help including been in to multimed efficiently the VBM accurately of including retail solution IV are XXXF, and and by strong control Omnicell of different technology VBM automated call footprint pharmacies. pharmacy the General communities gain hospital. their positive we UK, U.S., setting are create solution very has containers. customers We automation robotic only admixtures. Omnicell’s RIIS and adopting IV and is and a the In opportunity in-house small to patient combination pharmacy for XXXF commercial in-sourcing a multimed solution cost Tampa cost, operation more or Omnicell compounding Florida Hospital production what verity

expanding of to X-leg acquisitions strategy us evolving product updates. mission turn you deliver and our and our continued remain presence execution we integration Our and Performance for is relevance back specifically solutions. well change healthcare that outcomes. with and to environment, the total it of Peter future for The third good for some results. success I’ll improve of growth on today’s scale. customer our sets focused Center IV the believe for over momentum our pillar In we provider through combine practice historically We financial Aesynt solutions seeing continued and our that patient laid great are also the to portfolio foundation healthcare, and the and base strategic has cross-selling within progressing up

Peter Kuipers

Thank you, Randall.

related quarter from this GAAP which for Our XXX XXXX. gross product third from X% million or the the GAAP points with Earnings the XX.X% per XXXX Series GAAP share of sequentially, $X.XX, up up million launch. $XXX up a and quarter the driven were year. was XT up quarter the GAAP accordance EPS is was third ramp-up basis of revenue quarter margin or in by $X of of second in sensation $X.XX

restructuring-related GAAP In and related accounting addition acquisitions, fair results deferred Because report onetime expenses. non-GAAP compensation results to we events statements a in earnings to is intangible our useful and associated in GAAP onetime to and are our impacts of and inventory our with third component non-cash our non-GAAP quarter value the we expense on understand release press results as investors GAAP basis, use acquisition-related related on assets acquisition cost expenses financial acquisition financial A included stock statements. onetime compensation it is to for posted revenue to amortization and of We expenses which and website. stock amortization acquisition believe well and adjustments. that of results, as our addition full a reported reconciliation excludes is non-GAAP financial

Our quarter of up driven $XXX the non-GAAP revenues by million the XT of third Series were quarter prior continued from XXXX market introduction. X% ramp up the

of On were and basis, share above the quarter the is third XXXX, sequentially. $X.XX non-GAAP consensus earnings up $X.XX per in which

We’re seeing quarter. margin gross margin quarter the XXX good from points the non-GAAP gross as or in was expansion up prior XX.X% third basis

quarter expect sequentially. Non-GAAP the XT of million in and quarter Series continues adjusted fourth We we to and was the million gain in XXXX gross will pro to skill EBITDA $XX in ramp third $X up as margin increase for further manufacturing installation. or efficiencies the rollout up

& reported and Our Dispensing OmniRx MACHX also and dispensing Analytics, and Central business Automation Adherence. of Analytics Workstations, Omnicell Analytics Automation our Performance XT is Cabinets, Automated Center Medication Pharmacy, Omnicell of robotic Supply, & consists consisting segments, Anesthesia in systems.

as apartment-based Our an this Medication medication packaged of are that segment. packages software SureMed, pharmacists in by consumables create branded other used MACHX, The solutions. InPharmics as solutions equipment all retail are in and model well included segment of to which Aesynt Adherence consists aid adherence acquisitions synchronization adherence also Avantech, pharmacies now and software

Adherence in of Our and acquisitions Inc SurgiChem the MTS, are Ateb, included Medication segment.

reminder, As separately. expenses be cannot easily corporate certain to we applied either segment a report that

the third the Automation in third revenue million of operating the $XX quarter year & GAAP GAAP period for operating operating of of $XXX third quarter $XXX to million same GAAP segment the the GAAP of $XX On million same contributed third Non-GAAP million quarter Medication The up to XXXX in similar quarter GAAP million year. quarter income million income this in quarter $X.X the to compared in operating $X.X ago. profit last this third to operating segment and of $XX operating for non-GAAP ago. common $XX profit profit to XXXX. compared the Non-GAAP income quarter second income $XX of compares a a of in XXXX. year million zero compared last were $XX to million quarter $XX operating Adherence the the quarter quarter compared of our income XXXX. million quarter million the was for year million to in of of Non-GAAP GAAP of basis, $XX year. third segment $XXX,XXX expenses million quarter for in to of million contributed last the compares operating Analytics revenue the GAAP was $XX

margins. XX.X% cost, Moving up to from the second quarter, the and operating including margin, Non-GAAP integration in was third quarter. X% Aesynt in operating Ateb around

values. approximately expense for operating Excluding $X.X of million $X Non-GAAP cost interest loan non-GAAP margin loss expense the consisting integration approximately outstanding on was XX.X% quarter. million, around income mostly of the other and the the a third of net was

an to GAAP XX% expenses. average assuming tax we’re just to expense non-GAAP tax annual tax Finally, of rate

cash $X.X sheet third outstanding flow. balance decreased after debt XXXX, from balance and million quarter. In of down our to million paying the the quarter $X million our in cash to $XX Moving the by

from shipments days days prior days five quarter up invoice receivable. The down revenue. for shipment. shipments at of flow installs. quarter implementation quarter $XX period the second year. the for use third on cash eight fourth were the an accounts million build and of September info weeks for the by sales quarter time future on mostly outstanding from from was couple accounts we third Accounts three driven inventory the XXXX quarter sales $XX The inventory operations hard upon up between third receivable the larger to $XX driven last by million XX customer two future Series of XX, and from completion XT Inventories of quarter by were built and primarily receivable largely of million, was of quarter, outstanding in by driven Based to for implementations varies in average last The days million months days quarter increase our implementations. end an current towards XXXX and $XX agreements

we and approximately outstanding total debt from EBITDA September of XXXX of funded the measured over our months loan As $X.X. had balance as was XX, loan XX last million outstanding of bank leverage $XXX

Our was headcount X,XXX XX September this down at year at this XX from year. June X,XXX

the During number the dynamics product the third of we drivers introduction. XT underpinning executed quarter, a well on of Series

last Series week, delivered at growing earlier, over As day. are numbers as of approximately XT XXX customer the have XT Randall live every XXX and sites, Series sites we is mentioned both to

the of engineering expect we complete development, well the manufacturing, part are substantially next quarter. Centers phase the the of in the product Aesynt, of progressing for creation integration which of on Excellence As the we to fourth acquisition of of and

During the remainder continue the we on XXXX, of focus to following areas.

goods the dispensing expansion momentum; laying to First, into margin for one bookings we automated drive secondly, cabinets three, lines and cost accelerating further XT sold management. assembly as revenue and foundations consolidate; ramps cost reductions of continued gross

the to fourth Moving quarter.

For and to we and XXXX, non-GAAP revenue between expect $XXX of quarter $XXX GAAP the million. fourth be million

per non-GAAP $X.XX We between to fourth XXXX quarter expect earnings and the $X.XX share. be

but it’s calls, larger on As revenue and time from projects completion can such quarters. the note a quarterly previous growth rolling fluctuations rate to installation over multiple to impact impact discussed we in in earnings timing to don’t important given earnings quarter, measured expect time that

guidance. Let’s now move XXXX to total year

product million. bookings and between to XXXX $XXX be expect million We $XXX

be Despite XXXX. raising our our now the million ends revenue schedules. We between share. per non-GAAP feasibility $XXX non-GAAP XXXX the both be $XXX XXXX and expect implementation top expect now million to $X.XX XXXX expected midpoint management into GAAP guidance revenue by EPS $X.XX to and through narrowing and range in and range we We’re we of customers of non-GAAP guidance, a revenues lowering between XXXX are the revenue our

margin up year the Given quarter quarter. mid X% increased as the for non-GAAP be through Series in in points at the InPharmics of to demonstrating And quarter and this and the Ateb the XT about XXXX, using company’s the the fourth of ramp a and XX.X% operating in quarter breakeven related year of third guidance. gross cost around including in profitability quarter we integration first Aesynt, to expect margin, around revenue the hereby every and XX% increased second

Aesynt, Ateb non-GAAP Excluding for XX%, financial we in Again, slightly in fourth long the note cost it’s InPharmics the the guidance. term to with XXXX model. be above quarter and margin important integration in a and operating expect XXXX, acquisitions, when line items to couple included of reviewing our

XXXX, do for costs, $X results costs of for policy. These not integration non-GAAP for costs operating impacting mostly and team on we product million and our expenses, directly based all, to approximately non-GAAP Ateb of margin First and includes our integration-related that and integration cost. development integration the expenses related expected non-GAAP IT of of Aesynt accelerated project EPS, non-GAAP consist integration implementation Sarbanes-Oxley adjust

and annually. second million we’re tracking these in cost around expecting $XX XXXX, acquisitions of the Secondly from year are synergies to

the combined we XX% after demonstrated in integrating have of that overtime and the businesses acquired As our the full past, benefit margin will achieve scale target of confident getting the we business. operating non-GAAP the we’re

related by distinct around revenue are Series as two XXXX, introduction around up. equivalent EPS impacted financial of expect the are $X Lastly, be and results and credit a to to the secured faces, XT senior ramp the acquisitions to facility used year-over-year million profitability by to or $X.XX. headwind characterized interest Ateb finance expense non-GAAP product Reviewing the XXXX, manufacturing for Aesynt we XXXX

market to included It ramp customers. management Series XXXX up Series product ramp cost of ramp and also as in to half sub AcuDose then overhead First X% XT And implementation conversions at production of are and also the first launch XT the to has we the which product half of half. of the includes for XX% and revenue XT manufacturing the And implementing implementation optimal first second the Series Excellence absorption sales bookings conversion second growth XXXX, introductions and rate revenue included acceleration of return cost all the backlog the that it ramps. included have half of finally given ramps. sales we both all mentioned the before. the in of XTM and profit first absorption XT and also continued of up reductions growth XT improvement and adoption included Series the GX to for Centers To up cost of included of of in XT manufacturing cost as

to the term framework. Moving now financial long

Our remains financial term framework unchanged. long

of and non-GAAP growth; revenue organic Our and X% revenue consistent organic XX% to thirdly, operating on long of all term; two, the term growth framework financial first average XX% margin. X% over annual longer in

to For to XX% and we onwards expect growth term the XXXX onwards be long range. in organic X%

growth Product of end the for above and growth. XX% Bookings XXXX view is preliminary X% to at high potentially Our the

term of XXXX XX% Our for preliminary range. to X% view is also in revenue growth long the

more at towards However, range will of guidance end upside this the range. To Company during potential update, middle call point will our we hand feasibility with fourth back the I earnings provide to XXXX XX% the to Randall. XXXX X% of the the out call. round quarter this to The specific have higher

Randall Lipps

outcomes significant satisfying their satisfying and it this the employees the all be And put ASHP summary definitely really to medication healthcare just post-acute venues really the pleased bend who adoption because and And for way the or thing lot areas. to really that I And think innovation a me both it it’s quarter company. to a we’ll day. at impact excitement company exciting the of approach think XT. of all Well, the cost just satisfying introductions ramp manner. with like new and is improve significant well we and a more and I of the in into our we’re management feel excited demonstrating talking the about a of in execution grabbing curve product our is in our very across heart at non-acute And as the as we’re third continual marketplace to and across hospitals real seeing hold soul in in most it’s in and about systematic mission

concludes that So our prepared remarks.

up operator. Let’s open for it questions

Operator

question [Operator does from your from Capital. Instructions] first Hewitt Craig-Hallum come And Matt

Matt Hewitt

Two me. for

First you of QX. quarter. customer large the had customer in third sounds you the one I’m was wondering could that what’s hurricane in to It a pushed impact if all, quantify was like particular

If and you for quantify relates follow-up you’re that stating rate plan. the year, the then could question growth to your longer-term next that

to we look the X% year that into year and X% As you revenues potential But at in growth obviously M&A. if nine bookings next you’ve for historically translating XX% talk exclude then to your six XX% months. to growth next about

You’re exiting you. rate rate Thank or growth this a Why much next I’ll XX%. delta year figure faster to to rationalize out at here. faster up the wouldn’t I’m the hang listen. X% year? trying and than be just

Peter Kuipers

Matt. you, Thank

consensus. quarter, look performance a revenue if of you midpoint to So compared to the there was to third third of two the drivers third and at in kind the there about thirds was

question. on roughly, each in about the million factors outlook, the of is have for for momentum we preliminary Then those XXXX, our pipeline So your a definitely of lot of hurricane $X.X the for which specifically bookings. outlook

backlog months. which at So at can all see XX%. the we’re what course to And now So range. is visibility upside that what converts is today, also And it timing, in it’s see right? couple it is the are we now, the can preliminary, And into we it that XX% EI we how range, of middle XX%, with we potentially long-term bookings as will revenue we as close so that solidify growth for X% high and then you end – for that’s well. XX% above earlier think for we’ll And of see range, to said about of potential revenue will be very now EI X% visibility the the of to next over revenue. be the to timing growth

Matt Hewitt

Great. Thank you.

Peter Kuipers

Okay.

Operator

comes from Naidu Mohan next from And your Oppenheimer. question

Mohan Naidu

about I My questions think – fluid should segments, the you from think to are where to long-term versus how your Performance Center, rates the range? you various X% and growth about segment bridge we robotics right if the the XX% over Adherence XT Randy, that as as now we Peter bridge

Peter Kuipers

Yes. growth. specific a that don’t see line you can provide guidance kind we revenue product where There of where feel revenues, breakout we give specifically is we the a on

we of So at upgrade But course please cycle the of definitely have bookings And as make expected the driver Series biggest in course, ASHP as the think, forward, are I going always well. we sure dollar-wise would we’ll have have where XT order you so footprint growth XXXX is product cycle. other rate. But be But bookings we healthy nice compound. automated like and the introductions. multimed will like XT also lines for packager and show product PBM nice on run also associated small Those a the biggest software. now

But that we that accelerate itself up together leave for our – XT it can I all that where So would rate further it you now. if say will, of average as the growth overall. always. we’ll kind That’s

Mohan Naidu

get have quick margin it. to to different if will XX% Okay. would on able be you target. Got follow-up reach or the a that Then one in calendar you Maybe useful. to XXXX That that. be timeframe

Peter Kuipers

Yes.

will at the be that quarter. fourth in we remarks, it think said the XX% goal long-term So prepared we what in

in We the to business. interest continue

the at in in If there are are only really you the portfolio space today. look a our with in Omnicell and innovator opportunities segments portfolio integrated both where

come new come also with out with Greenfield products and refresh So product. but out

look multiple products have opportunities likely perspective, simultaneous another time little expected expense of revenue There as the a be we XT. maybe be growth. want percentage last Randall to to at from – years. we’ve leverage and market that definitely roughly R&D SG&A. impact a But new of at significant and But over couple have we of might to if won’t we said on growth bit our cost bookings we R&D do same both So done you earlier on call the over want the launches

and of investments some course that in to So requires extend R&D in SG&A. also

Mohan Naidu

Okay. it very Thank there. you I’ll leave much.

Peter Kuipers

Okay. Thank you.

Operator

And comes question your Jaffray. from next Piper from Nina Deka

Nina Deka

toward for the have for to other provide comprises insight happen some year Can range? you toward to above on of would what Or next the potential higher midpoint the get thanks what words, in question. the be that and XX%. Hi, to taking upside please the end

Randall Lipps

we traditionally days think I XX Well, now. talk next from year about

And later so the visibility thought a that new see say. in would the those are we I XX I is evaluate and of But that – there refine probably days is on. data in biggest about the upsides XT now equation probably again just growth. in think we so has lot we’ll But statements and

buy Those the lot and really sites, We of from just momentum backlog to in driver momentum our to the those. the feel XT which XT has obviously already customer forward. every IV biggest in just customer both, is base us shipped XXX backlog have the cycle, portion not Center about. move an reason about go to XX just do is maybe of is product, is go revenue then up months a that an and good take we’ve and a think large just I a continue but Performance little And as adopted we down XT in longer going would, to a to

Nina Deka

us insight inorganic what you your Thanks. X% size if target, of on And some also M&A the more growth strategy? long term in could give

Randall Lipps

the from unchanged has last this so many Yes, years.

for strategic we prepared talked we’ve that XX% then plans acquisitions organic strategic we and growth supplement achieve And growth growth when that So publicly about do in year we’ve to a acquisitions. we to those we – plans. five revenue and before aim X%

the they those over well. to X% going how do multi-year course, and the at acquisitions to timing If we into accretive to got We’ve We’ve CAGR as in to five a of those add to got fit years, profitability. to you to of look got segment. be the when contributing to add path

so longer term be X%. you a So it’s will, the roughly calculation at just over if to

Peter Kuipers

these would across go to lot I to we out software, system one all do continuum and just as care. of approaches we add these And enhance Ateb InPharmics A build acquisition large of that, are right. those with how the you the workflows, ecosystems including did got We’ve of targets just the workflows.

you software software cloud that or generally solution based enhance You that put margins on a the on drive and them tie those together side. based or higher know sets that’s

Nina Deka

internationally. more you in that the care bit type to can U.S. overtime? and point. this And also, setting of non-acute you to What how you’re continue also And little Okay. demand a to expect seeing describe do trend in

Randall Lipps

a package large as use sticky, going you particular medication for in automation enable as that’s you’re really And way an that product XXX because to particular why that VBM we’ve enabler really doing us take it ramp to comply, well it and we need the it to brings and up as single as they that pharmacy the it of happen and think to popular do VBM and pharmacy, packaging. that is and a to and started. either make I medications such makes call, patients said form or to want is if well that very to is easy a as a providers XXX Well, for patients

we’re we’re for that we’ve that So line. – in and year some next launched seeing product growth big

is I’d growth a and the say we just this to as continue UK additional So to our guess for on market provide continues don’t us broad East for – strong I Germany, know be market us. both big based Middle the launched products, France it I And year.

Peter Kuipers

and a non-acute you system. Maybe if last they just integrating more on the force systems, as their and at space, of and non-acute outpatient part facilities are more hospital centering comment into look

we acute the what solution integrated an see care So growth only has non-acute call settings. firstly to from we of in company a of different we are definitely continuum across that lot it, there, – because both

for really us. that positive So market is dynamic actually

Nina Deka

thanks. Great

Randall Lipps

our comment network on to Walgreens large with and help a medication one seen. adherence. provide add to building network announcement and you’ve today will recent a payers medication for adherence I other CVS as

definitely chain We we is. It that our adherence goes in reason us the have because what validates healthcare. for exactly see be And well marketplace. us, into med that know we every big it fact certainly some we for five don’t ago, really that you it but in today’s solution in it adherence years would lean almost and almost a of as exciting. changer knew action will sort opportunity game the med got And for

please. question Next

Operator

question & from next does Gene your Mannheimer And Dougherty from Instruction] [Operator come Co.

Gene Mannheimer

Congrats in afternoon. good the Thanks, all progress. good

I substitute are complimentary? you’re those or the positive. wanted for is The VBM What traction some that non-XT see, seeing to MXXXX, products questions. mean Let’s XXX very ask

Randall Lipps

There are right. a actually complimentary,

close solution PVX So a fully and the fully MXXXX a automated bigger thus footprint automated. is do can check pharmacy

packaging show that’s of later machine XX this installation ceiling, at so and would probably top the bigger printing will we of and the hospital systems. Just a first a I the and announce to actually labels the year, one, at site say, U.S. one

specialty printing have manual we is seal a pharmacies benefits a automated. It’s traction smaller pharmacies the retail the some it machine there. there. footprints, chains, has doesn’t we So the smaller is the step what that do [ph] call and But ceiling then for well. CBM as and highly it And many

CBM So on we the U.S., good in both and see the China. Europe in really momentum in machine some

Gene Mannheimer

with VBM to sales, more and progress will the is consumable change drive going it rate the to that there? in that Peter have Great. growth

Peter Kuipers

consumable as help well. revenue will that Yes,

Gene Mannheimer

you on don’t you’ve IV how product new recall but I Okay. And in that don’t I line? if any about characterize the then talked wins would side, know, there, your growth

Peter Kuipers

see for It’s an robotic makes And sense really into us. that perspective. a reason in now safety have hospital in and well. at IV half definitely system, area a from half the We about solution sourcing IV, you system, and don’t for for a prepared look as purchases couple mentioned a to capital efficiency you not a is more solution if times market, in we growth remarks is put that which the growth

Randall Lipps

traction because allowed is to year IV product on nice second which from presenting going the year. now is that year, grow so and to them and seeing Aesynt reps particular, really the we’re now a get product the pipeline next more really selling of every acquisition, product, that it’s So we’re in sales just grow our down and in accurately lot our that to that and it’s of get continue

So feel that really product. about good

Gene Mannheimer

Okay, Thank great. you.

Operator

questions And this to Lipps no Mr. any there go closing time. Randall remarks. We’ll at for are further

Randall Lipps

Day healthcare. for the our everybody Well, for Innovation’s at world I changing hope see to roll our innovation about

and healthcare. can how in they meds win just are everybody figure get out you their If we’re take their continuum meds going to in whatever and

going hope the for the us for it’s to So there today. Thanks be to excited impact things and and market about to healthcare joining have we term. long that how the talk to see show

Operator

this And you. today’s does conference Thank conclude call.

disconnect. You may now

Omnicell (OMCL) 26 Oct 172017 Q3 Earnings call transcript